HUMA vs. CRGX, RGNX, PRME, MESO, RLAY, KYTX, HLVX, EXAI, ITOS, and PROK
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include CARGO Therapeutics (CRGX), REGENXBIO (RGNX), Prime Medicine (PRME), Mesoblast (MESO), Relay Therapeutics (RLAY), Kyverna Therapeutics (KYTX), HilleVax (HLVX), Exscientia (EXAI), iTeos Therapeutics (ITOS), and ProKidney (PROK). These companies are all part of the "biological products, except diagnostic" industry.
CARGO Therapeutics (NASDAQ:CRGX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.
In the previous week, Humacyte had 9 more articles in the media than CARGO Therapeutics. MarketBeat recorded 18 mentions for Humacyte and 9 mentions for CARGO Therapeutics. Humacyte's average media sentiment score of 0.50 beat CARGO Therapeutics' score of 0.46 indicating that CARGO Therapeutics is being referred to more favorably in the media.
CARGO Therapeutics has higher earnings, but lower revenue than Humacyte.
93.2% of CARGO Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 1.4% of CARGO Therapeutics shares are held by company insiders. Comparatively, 23.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
CARGO Therapeutics currently has a consensus target price of $29.00, suggesting a potential upside of 42.02%. Humacyte has a consensus target price of $8.00, suggesting a potential upside of 26.38%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe CARGO Therapeutics is more favorable than Humacyte.
Humacyte's return on equity of 0.00% beat CARGO Therapeutics' return on equity.
Humacyte received 10 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CARGO Therapeutics an outperform vote while only 50.00% of users gave Humacyte an outperform vote.
Summary
CARGO Therapeutics beats Humacyte on 9 of the 13 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
